-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Merck & Co.
With the emergence of "cocktail therapy", AIDS has changed from a disease-causing disease that has become a fascinating disease to a chronic disease that can be controlled by drugs
Islatravir is an innovative NRTTI developed by Merck.
In this double-blind, placebo-controlled phase 1 clinical trial, 24 healthy participants implanted an implant containing different doses of islatravir in the upper arm, which can slowly release the drug in the body to achieve long-term maintenance drug treatment The effect of concentration
The test results showed that the three different doses of implants maintained the concentration of islatravir above the level of antiviral efficacy within 12 weeks
Note: This article is intended to introduce medical and health research, not to recommend treatment options
Reference materials:
[1] Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021.